Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
Ultragenyx (NASDAQ:RARE) announced that president and CEO Emil Kakkis, M.D., Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 4:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx (NASDAQ:RARE) announced that president and CEO Emil Kakkis, M.D., Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 4:00 PM ET.
A live and archived webcast will be available on Ultragenyx’s investor relations website.
Details
News Market Reaction – RARE
On Jun 4, the first trading day after this news, RARE closed 4.02% above the previous close.
Data tracked by StockTitan Argus for the Jun 4 session.
Key Figures
- Conference edition
- 47th
- Goldman Sachs Annual Global Healthcare Conference iteration
- Fireside chat time
- 4:00 PM ET
- Scheduled time on June 9, 2026
Historical Context
-
Inducement RSU grant to 11 newly hired non-executive officers.
-
Participation in Bank of America’s 2026 Healthcare Conference fireside chat.
-
Q1 2026 results with $136M revenue and reaffirmed 2026 guidance and milestones.
-
Announcement of May 5, 2026 conference call for Q1 2026 results.
-
Inducement RSU grant of 36,447 shares to new non-executive officers.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 PM ET.
The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.